Navigation Links
Anti-clotting agent helps reduce the incidence and impact of stent thrombosis during PCI
Date:3/27/2014

WASHINGTON, DC March 27, 2014 A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

CHAMPION PHOENIX was a prospective, double-blind, active-controlled trial which randomized 11,145 patients to receive intravenous cangrelor or oral clopidogrel administered at the time of PCI. In a previous analysis presented at TCT 2013 and published in the Journal of the American College of Cardiology, cangrelor significantly reduced periprocedural and 30-day ischemic events in patients undergoing PCI.

In this new analysis, an independent core laboratory (CRF) blinded to the treatment performed the angiographic analysis of 10,939 of the randomized patients. Stent thrombosis was defined as the occurrence of either intraprocedural ST (IPST) or ARC defined ST (definite or probable). Adverse events were adjudicated by an independent clinical events committee.

ST occurred in 120 patients (1.1 percent) at 48 hours and in 175 patients (1.6 percent) at 30 days. The occurrence of ST at 48 hours and 30 days was associated with a marked increase in 30-day mortality (OR [95%CI] = 15.3 [8.6, 27.2], p<0.001; and 55.2 [36.6, 83.3] p<0.001, respectively). IPST, ARC acute ST (≤24 hrs), and ARC subacute ST (1-30 days) occurred in 89 (0.8 percent), 32 (0.3 percent), and 60 (0.5 percent) patients respectively. Each type of ST was also associated with an increase in 30-day mortality (IPST: 17.4 [8.4, 36.1], p<0.001, ARC acute ST: 43.3 [18.1, 103.5], p<0.001, ARC sub-acute ST: 189.1, [107.9, 331.4], p<0.001).

"Regardless of the exact type of stent thrombosis, it remains associated with a high rate of death," stated Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart & Vascular Center, Professor of Medicine at Harvard Medical School, and Co-Chair of the CHAMPION program.

Cangrelor was associated with a significant reduction in 48-hour (0.8 vs. 1.4 percent, p=0.01) and 30-day ST (1.3 vs. 1.9 percent, p=0.01), compared with clopidogrel. Cangrelor also had consistent effect in IPST (0.6 vs. 1.0 percent, p=0.04), acute ARC ST (0.2 vs. 0.4 percent, p=0.8), and sub-acute ARC ST (0.5 vs. 0.6 percent, p=0.60). After multivariable analysis, the use of cangrelor was identified as an independent predictor of freedom of ST at 30 days.

"The benefits of cangrelor were consistent across all these different categories of stent thrombosis," stated Robert A. Harrington, MD, Chairman of Medicine and Bloomfield Professor of Medicine at Stanford University, and Co-Chair of the CHAMPION program.

"In the large-scale CHAMPION PHOENIX trial, the occurrence of stent thrombosis was strongly associated with increased mortality. Cangrelor use resulted in a significant reduction in ST, with consistent outcomes on intraprocedural, and outside the cath lab acute and sub-acute ARC defined ST," stated lead investigator Philippe Gnreux, MD. Dr. Gnreux is Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center. The CRF Angiographic Core Lab conducted the analyses.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Anti-clotting drugs yield similar results
2. Anti-clotting therapy may be used too often following orthopaedic surgery or trauma
3. Discovery could lead to anti-clotting drugs with less risk of bleeding
4. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
5. Pig stomach mucins are effective as anti-viral agents for consumer products
6. Imaging agents predict breast cancer response to endocrine therapy
7. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
8. New substances 15,000 times more effective in destroying chemical warfare agents
9. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
10. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
11. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: